Availability and costs of medicines for the treatment of tuberculosis in Europe.

ABSTRACT:

Objectives

To evaluate the access to comprehensive diagnostics and novel antituberculosis medicines in European countries.

Methods

We investigated the access to genotypic and phenotypic Mycobacterium tuberculosis drug susceptibility testing and the availability of antituberculosis drugs and calculated the cost of drugs and treatment regimens at major tuberculosis treatment centres in countries of the WHO European region where rates of drug-resistant tuberculosis are the highest among all WHO regions. Results were stratified by middle-income and high-income countries.

Results

Overall, 43 treatment centres from 43 countries participated in the study. For WHO group A drugs, the frequency of countries with the availability of phenotypic drug susceptibility testing was as

SUBMITTER: Gunther G 

PROVIDER: S-EPMC9801521 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature